4-(isobutyrylamino)-1H-imidazo[4,5-c]pyridine | 881844-12-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 4-(isobutyrylamino)-1H-imidazo[4,5-c]pyridine
• 英文别名: N-(1H-imidazo[4,5-c]pyridin-4-yl)-2-methylpropanamide
• CAS: 881844-12-8
• 化学式: C₁₀H₁₂N₄O
• 分子量: 204.231
• InChiKey: OYOJBFUVQCZGLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  70.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(isobutyrylamino)-1H-imidazo[4,5-c]pyridine 在 氢氧化钾 、 tris[2-(2-methoxyethyl)ethyl]amine 、 硫酸 、 硝酸 作用下， 以 乙腈 为溶剂， 反应 1.08h， 生成 4-amino-3-[2'-deoxy-3',5'-di-O-(4-toluoyl)-β-D-erythro-pentofuranosyl]-7-nitro-3H-imidazo[4,5-c]pyridine
  参考文献：
  名称：

  Synthesis of 3-deaza-3-nitro-2′-deoxyadenosine

  摘要：

  Photoactivable deoxyadenosine mimic, 3-deaza-3-nitro-2'-deoxyadetiosine (2), was prepared using two different synthetic routes. The first route involved base catalyzed glycosylation of 3-deaza-3-nitroadenine, which was prepared by regioselective nitration of 3-deazaadenine. In the second route, the convertible nucleoside 6-O-(2,4,6-trimethylphenyl)-3-deaza-2'-deoxyadenosine (28) was used to introduce 6-NH2 group in the last step. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.10.040
• 作为产物：
  描述：

  2,4-二氯-3-硝基吡啶 在 吡啶 、 氢气 、 乙酸酐 、 镍 、 三乙胺 、 三氟乙酸 、 肼 作用下， 以 甲醇 、 丙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.5h， 生成 4-(isobutyrylamino)-1H-imidazo[4,5-c]pyridine
  参考文献：
  名称：

  Synthesis of 3-deaza-3-nitro-2′-deoxyadenosine

  摘要：

  Photoactivable deoxyadenosine mimic, 3-deaza-3-nitro-2'-deoxyadetiosine (2), was prepared using two different synthetic routes. The first route involved base catalyzed glycosylation of 3-deaza-3-nitroadenine, which was prepared by regioselective nitration of 3-deazaadenine. In the second route, the convertible nucleoside 6-O-(2,4,6-trimethylphenyl)-3-deaza-2'-deoxyadenosine (28) was used to introduce 6-NH2 group in the last step. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.10.040

文献信息

• Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections
  申请人：Chu David C.K.

  公开号：US20090270431A1

  公开（公告）日：2009-10-29

  The present invention relates to compounds according to the structure (I), Where B is formula (Ia), formula (Ib) or formula (Ic); A is H, OR 2 or halogen (F, Cl, Br, I, preferably F or Br, more preferably F); A′ is H, OR2 or halogen (F, Cl, Br, I, preferably F or Br, more preferably F); A″ is H or OR 1 , with the proviso that when A′ is OR, A is H; and when A is OR 2 , A′ is H; X is C—R 3 or N; Y is C—R 3 or N; preferably X or Y is N and X and Y are not both simultaneously N; R 3 is H or C 1 -C 3 alkyl; D is H or NHR 2 ; E is absent or H; G is O or NHR 2 ; J is N or C—R 4 ; K is N or C—H; R 4 is H, halogen (F, Cl, Br, I), CN, —C(═O)NH 2 , NH 2 , NO 2 , —C═C—H (cis or trans) or —C≡C—H; R a is H or CH 3 ; Each R 1 is independently H, an acyl group, a C 1 -C 20 alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group; Each R 2 is independently H, an acyl group, a C 1 -C 20 alkyl or ether group; and Pharmaceutically acceptable salts, solvates or polymorphs thereof.

  本发明涉及结构式(I)的化合物，其中B为公式(Ia)，公式(Ib)或公式(Ic)；A为H，OR2或卤素（F，Cl，Br，I，优选F或Br，更优选F）；A′为H，OR2或卤素（F，Cl，Br，I，优选F或Br，更优选F）；A″为H或OR1，但当A′为OR时，A为H；当A为OR2时，A′为H；X为C—R3或N；Y为C—R3或N；优选X或Y为N，且X和Y不同时为N；R3为H或C1-C3烷基；D为H或NHR2；E不存在或为H；G为O或NHR2；J为N或C—R4；K为N或C—H；R4为H，卤素（F，Cl，Br，I），CN，—C（═O）NH2，NH2，NO2，—C═C—H（顺式或反式）或—C≡C—H；Ra为H或CH3；每个R1独立地为H，酰基，C1-C20烷基或醚基，磷酸盐，二磷酸盐，三磷酸盐，磷酸二酯基；每个R2独立地为H，酰基，C1-C20烷基或醚基；以及其药学上可接受的盐，溶剂或多晶形式。
• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GlaxoSmithKline Intellectual Property (No.2) Limited

  公开号：US20170355705A1

  公开（公告）日：2017-12-14

  The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
• Synthesis of 3-deaza-3-nitro-2′-deoxyadenosine
  作者：Caroline Crey-Desbiolles、Mitsuharu Kotera

  DOI：10.1016/j.bmc.2005.10.040

  日期：2006.3

  Photoactivable deoxyadenosine mimic, 3-deaza-3-nitro-2'-deoxyadetiosine (2), was prepared using two different synthetic routes. The first route involved base catalyzed glycosylation of 3-deaza-3-nitroadenine, which was prepared by regioselective nitration of 3-deazaadenine. In the second route, the convertible nucleoside 6-O-(2,4,6-trimethylphenyl)-3-deaza-2'-deoxyadenosine (28) was used to introduce 6-NH2 group in the last step. (c) 2005 Elsevier Ltd. All rights reserved.